Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 23, 2023Terminated
Hide Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 23, 2023Terminated
Condition(s):Multiple MyelomaLast Updated:June 30, 2022Completed
Condition(s):Multiple MyelomaLast Updated:December 8, 2023Completed
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 2, 2021Active, not recruiting
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:April 12, 2023Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 20, 2023Terminated
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:July 24, 2023Active, not recruiting
Condition(s):Refractory Multiple MyelomaLast Updated:October 12, 2023Active, not recruiting
Condition(s):Relapsed Refractory Multiple MyelomaLast Updated:January 16, 2024Suspended
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:January 25, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.